Cite
HARVARD Citation
Merseburger, A. et al. (2022). Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study. Lancet oncology. 23 (11), pp. 1398-1408. [Online].